Category News

FINTLEPLA®▼ (fenfluramine) oral solution gains approval in Japan as adjunctive therapy for seizures linked with Lennox-Gastaut syndrome (LGS)

UCB’s FINTEPLA®▼ (fenfluramine) oral solution has received approval from the Japanese Ministry of Health, Labour, and Welfare (MHLW) for treating seizures linked with Lennox-Gastaut syndrome (LGS) as an additional therapy alongside other anti-epileptic medications for patients aged two and above.…

Read MoreFINTLEPLA®▼ (fenfluramine) oral solution gains approval in Japan as adjunctive therapy for seizures linked with Lennox-Gastaut syndrome (LGS)

Six-Year Efficacy of Novartis Kesimpta® in Newly Diagnosed Relapsing MS Patients

Novartis has unveiled findings from the ALITHIOS open-label extension study, spotlighting the enduring effectiveness of continuous Kesimpta® (ofatumumab) treatment for up to six years in individuals recently diagnosed with relapsing multiple sclerosis (RMS). This group, characterized by commencing treatment within…

Read MoreSix-Year Efficacy of Novartis Kesimpta® in Newly Diagnosed Relapsing MS Patients

WuXi Biologics Chosen for S&P Global Sustainability Yearbook 2024

WuXi Biologics, known as WuXi Bio (2269.HK), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly announces its selection for the prestigious S&P Global Sustainability Yearbook 2024 (“Yearbook”) in recognition of its outstanding sustainability performance throughout 2023. The…

Read MoreWuXi Biologics Chosen for S&P Global Sustainability Yearbook 2024

Comparison Study Shows TheracosBio’s BRENZAVVY® Matches Dapagliflozin in Effectiveness for Chinese Patients with Type 2 Diabetes

TheracosBio has recently published a study titled “Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: a 24-week, randomized, double-blind, active-controlled, phase 3 trial” in the Journal of…

Read MoreComparison Study Shows TheracosBio’s BRENZAVVY® Matches Dapagliflozin in Effectiveness for Chinese Patients with Type 2 Diabetes

Jazz Pharmaceuticals to Present Comprehensive Neuroscience Portfolio at Annual American Academy of Neurology Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has revealed that its expansive neuroscience portfolio and pipeline will be prominently featured at the 76th Annual American Academy of Neurology Meeting (AAN), taking place from April 13-18, 2024, in Denver. A total of 13…

Read MoreJazz Pharmaceuticals to Present Comprehensive Neuroscience Portfolio at Annual American Academy of Neurology Meeting

Baxter Broadens Pharmaceutical Portfolio with Fresh Injectable Offerings in the U.S.

Baxter International Inc. (NYSE:BAX), renowned globally for its excellence in injectables, anesthesia, and drug compounding, has unveiled a significant expansion of its Pharmaceuticals portfolio with the introduction of five new injectable products in the United States. Alok Sonig, Executive Vice…

Read MoreBaxter Broadens Pharmaceutical Portfolio with Fresh Injectable Offerings in the U.S.

Jazz Pharmaceuticals Set to Unveil Broad Range of Neuroscientific Innovations at American Academy of Neurology’s Annual Gathering

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has revealed that it will present 13 abstracts from its extensive neuroscience portfolio and pipeline at the 76th Annual American Academy of Neurology Meeting (AAN), scheduled for April 13-18, 2024, in Denver. Among these presentations,…

Read MoreJazz Pharmaceuticals Set to Unveil Broad Range of Neuroscientific Innovations at American Academy of Neurology’s Annual Gathering

Vertex Strikes Deal to Purchase Alpine Immune Sciences

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in…

Read MoreVertex Strikes Deal to Purchase Alpine Immune Sciences

Teva’s Latest Pharmacokinetic Modeling Data Shows UZEDY® Benefits for Schizophrenia Patients at SIRS 2024

Teva Pharmaceuticals Unveils Promising PK Modeling Data and Clinical Insights at SIRS 2024 At the Schizophrenia International Research Society (SIRS) 2024 Congress, Teva Pharmaceuticals, a leading U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has revealed significant…

Read MoreTeva’s Latest Pharmacokinetic Modeling Data Shows UZEDY® Benefits for Schizophrenia Patients at SIRS 2024

Positive Findings: Zilebesiran Combined with Antihypertensives for Uncontrolled Hypertension

 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) has unveiled promising outcomes from the KARDIA-2 Phase 2 investigation, evaluating the effectiveness and safety of zilebesiran when combined with one of three standard antihypertensive medications: a thiazide-like diuretic (indapamide), calcium channel blocker (amlodipine), or…

Read MorePositive Findings: Zilebesiran Combined with Antihypertensives for Uncontrolled Hypertension